Cellosaurus MDA-MB-453 (CVCL_0418)

Cell line name MDA-MB-453
Synonyms MDA-MB 453; MDA MB 453; MDA-MB453; MDAMB453; MDA-453; MDA453
Accession CVCL_0418
Resource Identification Initiative To cite this cell line use: MDA-MB-453 (RRID:CVCL_0418)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: ICBP43 breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: PI3K genetic alteration cell panel (ATCC TCP-1028).
Doubling time: 38 hours (PubMed=25984343); ~50-60 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: AR p.Gln868His (PubMed=22719059).
Sequence variation: KRAS p.Gly13Asp (PubMed=22121396).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Metabolome analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: MDA-MB-345; In Cosmic 1129656.
Disease Breast adenocarcinoma (NCIt: C5214)
Derived from metastatic site: Pericardial effusion.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_6421 (MDA-kb2)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; KCLB; PubMed=25877200; RCB

Markers:
AmelogeninX
CSF1PO10,12
D13S31712
D16S5399
D18S5115,20
D21S1129,31
D3S135815
D5S81811
D7S82010
D8S117910,12
FGA18,23
Penta D9,10
Penta E11
TH016
TPOX10
vWA17,18
Web pages http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/MDA-MB-453.html
http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=MDA-MB-453
http://lincs.hms.harvard.edu/resources/reagents/icbp43/
http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-56.html
http://tcpaportal.org/mclp/
Publications

PubMed=730202; DOI=10.1007/BF02616120
Cailleau R.M., Olive M., Cruciger Q.V.J.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
In Vitro 14:911-915(1978)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=11687795; DOI=10.1038/ng754
Snijders A.M., Nowak N., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G.
Assembly of microarrays for genome-wide measurement of DNA copy number.
Nat. Genet. 29:263-264(2001)

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE
Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Am. J. Clin. Pathol. 117:81-89(2002)

PubMed=12353263; DOI=10.1002/gcc.10107
Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Genes Chromosomes Cancer 35:204-218(2002)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=16142302; DOI=10.3892/ijo.27.4.881
de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J.
Molecular characterization of breast cancer cell lines by a low-density microarray.
Int. J. Oncol. 27:881-892(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=21378333
Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.
Reassessment of estrogen receptor expression in human breast cancer cell lines.
Anticancer Res. 31:521-527(2011)

PubMed=22121396; DOI=10.3892/ol.2011.375
Vranic S., Gatalica Z., Wang Z.-Y.
Update on the molecular profile of the MDA-MB-453 cell line as a model for apocrine breast carcinoma studies.
Oncol. Lett. 2:1131-1137(2011)

PubMed=22414580; DOI=10.1158/0008-5472.CAN-11-3711
Geiger T., Madden S.F., Gallagher W.M., Cox J., Mann M.
Proteomic portrait of human breast cancer progression identifies novel prognostic markers.
Cancer Res. 72:2428-2439(2012)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=22719059; DOI=10.1530/ERC-12-0065
Moore N.L., Buchanan G., Harris J.M., Selth L.A., Bianco-Miotto T., Hanson A.R., Birrell S.N., Butler L.M., Hickey T.E., Tilley W.D.
An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity.
Endocr. Relat. Cancer 19:599-613(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021
Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B.
Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines.
J. Chromatogr. B 1000:95-104(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; HTB-131
BCRC; 60429
DSMZ; ACC-65
ICLC; HTL01013
IZSLER; BS TCL 247 - Discontinued
KCLB; 30131
NCBI_Iran; C214
RCB; RCB1192
Cell line databases/resources CLDB; cl3411
CLDB; cl7187
CCLE; MDAMB453_BREAST
CCRID; 3111C0001CCC000016
CCRID; 3131C0001000700035
Cosmic-CLP; 908122
GDSC; 908122
IGRhCellID; MDAMB453
LINCS_HMS; 50334
LINCS_LDP; LCL-1485
Lonza; 837
Ontologies BTO; BTO:0001908
CLO; CLO_0007640
CLO; CLO_0050867
EFO; EFO_0001215
MCCL; MCC:0000315
Biological sample resources BioSample; SAMN01821576
BioSample; SAMN01821647
BioSample; SAMN03472899
Chemistry resources ChEMBL-Cells; CHEMBL3307596
ChEMBL-Targets; CHEMBL614334
Gene expression databases GEO; GSM813
GEO; GSM115117
GEO; GSM217590
GEO; GSM219956
GEO; GSM274656
GEO; GSM344355
GEO; GSM344405
GEO; GSM350530
GEO; GSM481307
GEO; GSM783928
GEO; GSM847417
GEO; GSM844602
GEO; GSM887300
GEO; GSM888375
GEO; GSM1008910
GEO; GSM1053710
GEO; GSM1172983
GEO; GSM1384316
GEO; GSM1264071
GEO; GSM1264075
GEO; GSM1264113
GEO; GSM1264117
GEO; GSM1374660
GEO; GSM1374661
GEO; GSM1374662
GEO; GSM1401667
GEO; GSM1421431
GEO; GSM1664568
GEO; GSM1661983
GEO; GSM1670086
Polymorphism and mutation databases Cosmic; 687497
Cosmic; 871157
Cosmic; 897426
Cosmic; 904383
Cosmic; 908122
Cosmic; 923060
Cosmic; 934529
Cosmic; 979712
Cosmic; 991326
Cosmic; 997920
Cosmic; 1010927
Cosmic; 1018468
Cosmic; 1027056
Cosmic; 1044223
Cosmic; 1046931
Cosmic; 1047694
Cosmic; 1129656
Cosmic; 1136356
Cosmic; 1152522
Cosmic; 1176651
Cosmic; 1287911
Cosmic; 1289401
Cosmic; 1308995
Cosmic; 1434956
Cosmic; 1524345
Cosmic; 1601924
Cosmic; 1603222
Cosmic; 1609457
Cosmic; 2165012
Cosmic; 2301532
Cosmic; 2318375
Cosmic; 2564832
Proteomic databases PRIDE; PXD000309